Jean Pierre Delord - JoVE Visualize

Showing results (141-150 of 178) with videos related to

Pageof 18

Sort By:

European Journal of Cancer (Oxford, England : 1990)|November 8, 2020

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.

The Lancet. Oncology|September 7, 2015

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.

Nature Medicine|April 8, 2025

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.

JCO Precision Oncology|September 11, 2020

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 TrialClémence Basse, Claire Morel, Céline Callens, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.

The Lancet. Oncology|September 13, 2020

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.

Cancers|June 22, 2023

Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.

Journal for Immunotherapy of Cancer|October 24, 2020

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.

The Lancet. Gastroenterology & Hepatology|February 3, 2022

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.

Pageof 18

Showing results (141-150 of 178) with videos related to

Sort By:

Pageof 18

European Journal of Cancer (Oxford, England : 1990)|November 8, 2020

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.

The Lancet. Oncology|September 7, 2015

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.

Nature Medicine|April 8, 2025

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialOlivier Trédan, Damien Pouessel, Nicolas Penel, et al.

JCO Precision Oncology|September 11, 2020

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 TrialClémence Basse, Claire Morel, Céline Callens, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.

The Lancet. Oncology|September 13, 2020

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.

Cancers|June 22, 2023

Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.

Journal for Immunotherapy of Cancer|October 24, 2020

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.

The Lancet. Gastroenterology & Hepatology|February 3, 2022

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 studyAurelien Marabelle, Philippe A Cassier, Marwan Fakih, et al.

Pageof 18